Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma

Blood (2024) 144 (Supplement 1): 230.

https://doi.org/10.1182/blood-2024-209616

Published: 2024

Journal Articles

MYD88 L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8

Elisa Mandato, Qingsheng Yan, Jing Ouyang, Julia Paczkowska, Yan Qin, Yansheng Hao, Kamil Bojarczuk, Julia Hansen, Björn Chapuy, Scott J. Rodig, Sumbul Jawed Khan, Robert A. Redd, Margaret A. Shipp

Blood (2023) 142 (14): 1219–1232.

https://doi.org/10.1182/blood.2023019865

Published: 2023

Includes: Supplemental data

Journal Articles

SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma

Blood (2022) 139 (4): 538–553.

https://doi.org/10.1182/blood.2021012081

Published: 2022

Includes: Supplemental data

Journal Articles

MYD88 L265P Augments Proximal B-Cell Receptor Signaling in Large B-Cell Lymphomas Via an Interaction with DOCK8

Elisa Mandato, Qingsheng Yan, Jing Ouyang, Julia Paczkowska, Yan Qin, Yansheng Hao, Kamil Bojarczuk, Julia Hansen, Lee N. Lawton, Margaret A. Shipp

Blood (2021) 138 (Supplement 1): 1324.

https://doi.org/10.1182/blood-2021-153024

Published: 2021

Journal Articles

Inhibition of PIM Kinases in Diffuse Large B-Cell Lymphoma Cells Targets MYC-Dependent Transcriptional Program, Increases CD20 Expression and Augments the Efficacy of Anti-CD20 Antibodies

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-134778

Published: 2020

Journal Articles

Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade

Blood (2019) 134 (Supplement_1): 1493.

https://doi.org/10.1182/blood-2019-131904

Published: 2019

Journal Articles

Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL

Kamil Bojarczuk, Kirsty Wienand, Jeremy A. Ryan, Linfeng Chen, Mariana Villalobos-Ortiz, Elisa Mandato, Joanna Stachura, Anthony Letai, Lee N. Lawton, Bjoern Chapuy, Margaret A. Shipp

Blood (2019) 133 (1): 70–80.

https://doi.org/10.1182/blood-2018-08-872465

Published: 2019

Includes: Supplemental data

Journal Articles

Targeted Inhibition of PI3K α/δ Is Synergistic with BCL-2 Blockade in Genetically Defined Subtypes of DLBCL

Kamil Bojarczuk, PhD, Kirsty Wienand, PhD, Jeremy A. Ryan, SM, Linfeng Chen, PhD, Mariana Villalobos-Ortiz, Elisa Mandato, PhD, Joanna Stachura, MSc, Lee N. Lawton, PhD, Anthony Letai, MD PhD, Bjoern Chapuy, MDPhD, Margaret A. Shipp, MD

Blood (2018) 132 (Supplement 1): 39.

https://doi.org/10.1182/blood-2018-99-113647

Published: 2018

Journal Articles

HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies

Blood (2017) 130 (14): 1628–1638.

https://doi.org/10.1182/blood-2016-08-736066

Published: 2017

Includes: Supplemental data

Journal Articles

BCR signaling inhibitors differ in their ability to overcome Mcl-1–mediated resistance of CLL B cells to ABT-199

Kamil Bojarczuk, Binu K. Sasi, Stefania Gobessi, Idanna Innocenti, Gabriele Pozzato, Luca Laurenti, Dimitar G. Efremov

Blood (2016) 127 (25): 3192–3201.

https://doi.org/10.1182/blood-2015-10-675009

Published: 2016

Includes: Supplemental data

Journal Articles

Inhibition of SYK More Effectively Overcomes MCL-1 Mediated ABT-199 Resistance of BCR-Stimulated CLL Cells Than Inhibition of BTK or PI3Kdelta

Kamil Bojarczuk, PhD, Binu K Sasi, PhD, Stefania Gobessi, PhD, Idanna Innocenti, MD, Luca Laurenti, MD, Dimitar G Efremov, MD PhD

Blood (2015) 126 (23): 489.

https://doi.org/10.1182/blood.V126.23.489.489

Published: 2015

Journal Articles

HDAC Inhibitors As Potential New Agents Improving the Efficacy of Monoclonal Antibodies

Malgorzata Bobrowicz, MSc, Michal Dwojak, DMD, Agata Malenda, MD PhD, Kamil Bojarczuk, MSc, Marta Siernicka, MSc, Beata Pyrzynska, PhD, Ewa Lech-Maranda, MD PhD, Tomasz Stoklosa, MD PhD, Magdalena Winiarska, PhD, Jakub Golab, MD PhD

Blood (2014) 124 (21): 3641.

https://doi.org/10.1182/blood.V124.21.3641.3641

Published: 2014

Journal Articles

Influence of Btk Inhibitors on Antitumor Activity of Natural Killer Cells

Marta Siernicka, MSc, Kamil Bojarczuk, MSc, Malgorzata Bobrowicz, MSc, Michal Dwojak, DMD, Beata Pyrzynska, PhD, Daniel Olive, MD, PhD, Magdalena Winiarska, PhD

Blood (2014) 124 (21): 2742.

https://doi.org/10.1182/blood.V124.21.2742.2742

Published: 2014

Journal Articles

HDAC6 Inhibition Increases CD20 Level and Improves The Efficacy Of Anti-CD20 Monoclonal Antibodies

Malgorzata Bobrowicz, MSc, Michal Dwojak, Kamil Bojarczuk, MSc, Magdalena Winiarska, PhD, Jakub Golab, M.D., Ph.D.

Blood (2013) 122 (21): 4406.

https://doi.org/10.1182/blood.V122.21.4406.4406

Published: 2013

Journal Articles

Inhibitors Of B-Cell Receptor Molecules Affect Surface CD20 and Impair Antitumor Activity Of Anti-CD20 Monoclonal Antibodies

Kamil Bojarczuk, MSc, Magdalena Winiarska, PhD, Malgorzata Bobrowicz, MSc, Michal Dwojak, Nina Miazek, Piotr Zapala, Dimitar G Efremov, MD, PhD, Jakub Golab, M.D., Ph.D.

Blood (2013) 122 (21): 4217.

https://doi.org/10.1182/blood.V122.21.4217.4217

Published: 2013

Journal Articles

Inhibitors Of Src Family and AKT Regulate The Activity Of CD20 Promoter

Beata Pyrzynska, PhD, Kamil Bojarczuk, MSc, Magdalena Winiarska, PhD, Jacek Bil, MD, PhD, Nina Miazek, Piotr Zapala, Malgorzata Bobrowicz, MSc, Michal Dwojak, Marta Siernicka, Jakub Golab, M.D., Ph.D.

Blood (2013) 122 (21): 1838.

https://doi.org/10.1182/blood.V122.21.1838.1838

Published: 2013

Journal Articles

Src Family Tyrosine Kinases Are Involved in the Transcriptional Regulation of CD20 Levels

Magdalena Winiarska, PhD, Jacek Bil, MD, PhD, Kamil Bojarczuk, BSc, Dominika Nowis, MD, PhD, Malgorzata Wanczyk, MSc, Michal Dwojak, Grzegorz Basak, MD, PhD, Tomasz Stoklosa, MD, PhD, Jakub Golab, MD, PhD

Blood (2011) 118 (21): 1661.

https://doi.org/10.1182/blood.V118.21.1661.1661

Published: 2011

Journal Articles

Prenyl Transferases Are Involved in the Regulation of CD20 Levels and Influence Anti-CD20 Monoclonal Antibody-Mediated Activation of Complement-Dependent Cytotoxicity,

Dominika Nowis, MD, PhD, Magdalena Winiarska, PhD, Jacek Bil, MD, PhD, Angelika Muchowicz, MSc, Malgorzata Wanczyk, MSc, Eliza Glodkowska-Mrowka, MD, Kamil Bojarczuk, BSc, Malgorzata Firczuk, PhD, Ewa Wilczek, PhD, Malgorzata Wachowska, MSc, Justyna Chlebowska, MSc, Michal Dwojak, Marta Miaczynska, PhD, Tomasz Stoklosa, MD, PhD, Jakub Golab, MD, PhD

Blood (2011) 118 (21): 3722.

https://doi.org/10.1182/blood.V118.21.3722.3722

Published: 2011

Journal Articles

Sorafenib Affects Membrane Complement Inhibitors and Improves Antitumor Activity of Rituximab,

Jakub Golab, MD, PhD, Jacek Bil, MD, PhD, Kamil Bojarczuk, BSc, Dominika Nowis, MD, PhD, Marcin Okroj, Ph.D., Grzegorz Basak, MD, PhD, Tomasz Stoklosa, MD, PhD, Magdalena Winiarska, PhD

Blood (2011) 118 (21): 3723.

https://doi.org/10.1182/blood.V118.21.3723.3723

Published: 2011

Journal Articles

Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity

Jacek Bil, Magdalena Winiarska, Dominika Nowis, Kamil Bojarczuk, Anna Dąbrowska-Iwanicka, Grzegorz W. Basak, Kazimierz Sułek, Marek Jakobisiak, Jakub Golab

Blood (2010) 115 (18): 3745–3755.

https://doi.org/10.1182/blood-2009-09-244129

Published: 2010

Includes: Supplemental data

NARROW

Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma

MYD88 L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8

SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma

MYD88 L265P Augments Proximal B-Cell Receptor Signaling in Large B-Cell Lymphomas Via an Interaction with DOCK8

Inhibition of PIM Kinases in Diffuse Large B-Cell Lymphoma Cells Targets MYC-Dependent Transcriptional Program, Increases CD20 Expression and Augments the Efficacy of Anti-CD20 Antibodies

Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade

Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL

Targeted Inhibition of PI3K α/δ Is Synergistic with BCL-2 Blockade in Genetically Defined Subtypes of DLBCL

HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies

BCR signaling inhibitors differ in their ability to overcome Mcl-1–mediated resistance of CLL B cells to ABT-199

Inhibition of SYK More Effectively Overcomes MCL-1 Mediated ABT-199 Resistance of BCR-Stimulated CLL Cells Than Inhibition of BTK or PI3Kdelta

HDAC Inhibitors As Potential New Agents Improving the Efficacy of Monoclonal Antibodies

Influence of Btk Inhibitors on Antitumor Activity of Natural Killer Cells

HDAC6 Inhibition Increases CD20 Level and Improves The Efficacy Of Anti-CD20 Monoclonal Antibodies

Inhibitors Of B-Cell Receptor Molecules Affect Surface CD20 and Impair Antitumor Activity Of Anti-CD20 Monoclonal Antibodies

Inhibitors Of Src Family and AKT Regulate The Activity Of CD20 Promoter

Src Family Tyrosine Kinases Are Involved in the Transcriptional Regulation of CD20 Levels

Prenyl Transferases Are Involved in the Regulation of CD20 Levels and Influence Anti-CD20 Monoclonal Antibody-Mediated Activation of Complement-Dependent Cytotoxicity,

Sorafenib Affects Membrane Complement Inhibitors and Improves Antitumor Activity of Rituximab,

Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only